Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics Public Limited Company - Ordinary Shares (NQ: HZNP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Horizon Therapeutics Public Limited Company - Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks
From Horizon Therapeutics plc
Via Business Wire
What 6 Analyst Ratings Have To Say About Horizon Therapeutics
Horizon Therapeutics (NASDAQ:HZNP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings for Horizon Therapeutics
Analysts have provided the following ratings for Horizon Therapeutics (NASDAQ:HZNP) within the last quarter: 
Via Benzinga
New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics Inks Option Agreement For Atopic Dermatitis Candidate
Via Benzinga
Horizon Therapeutics Earnings Perspective: Return On Capital Employed
  
Via Benzinga
Expert Ratings for Horizon Therapeutics
Analysts have provided the following ratings for Horizon Therapeutics (NASDAQ:HZNP) within the last quarter: 
Via Benzinga
Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named to Newsweek’s 2022 Top 100 Most Loved Workplaces
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022
From Horizon Therapeutics plc
Via Business Wire
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
From Horizon Therapeutics plc
Via Business Wire
Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Makes Founding Gift to Support the University of Notre Dame’s Patient Advocacy Initiative
From Horizon Therapeutics plc
Via Business Wire
Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Joins the International Agency for the Prevention of Blindness (IAPB) to Encourage People to #LoveYourEyes this World Sight Day
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces $500 Million Share Repurchase Program
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2022 List
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®
From Horizon Therapeutics plc
Via Business Wire
Why Viridian's CEO Isn't Sweating His Company's Second-Place Position
The company didn't plan to be first in thyroid eye disease. But it hopes to be best. 
Via Investor's Business Daily
Horizon Therapeutics plc Announces Plans to Expand its Development and Manufacturing Facility in Waterford, Ireland
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From Horizon Therapeutics plc
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 62 companies set new 52-week lows. 
Via Benzinga
New Contender Viridian Takes Aim At Horizon's Eye Drug, And Rockets
Horizon has the only approved thyroid eye disease treatment in the U.S., for now. 
Via Investor's Business Daily
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
From Horizon Therapeutics plc
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.